Abstract
Background Having a prevalence of almost 64 million patients globally, Heart Failure (HF) remains a leading cause of cardiac death with high morbidity and mortality rates despite constant updates in diagnostic and therapeutic measures. One of the main reasons behind this might be a delay in initiating treatment.
Purpose To obtain a method of screening patients for Heart Failure even before they develop symptoms.
Methods An Artificial Intelligence-based algorithm, named Heart Failure Predictor (HFP), born from mathematical calculations of a patented formula, came up with a cutting-edge solution that can predict the chances of HF in patients not suffering from any symptoms of Heart Failure. HFP was applied to data from the Framingham Heart Study as a retrospective analysis. LVEF and NT pro-BNP levels were used as a method of correlation. Asymptomatic patients who had been followed up extensively for at-least 24 months were included, while patients already diagnosed with HF were excluded.
Results Data from 20896 patients were analysed.
17 out of 1230 were false positive while 31 out of 19660 were false negative.
Thus, HFP has a Positive Predictive Value of 98.6% and a Specificity of 99.9%.
Discussion Early screening and detection may lead to vast improvements in HF treatment efficacy. HFP fills this need with a new classification of HF, “Impending Heart Failure”, and synonymously “Ray’s Disease”.
Apart from screening HF patients, HFP can also be used for continuous monitoring of LVEF in cardiac beds, bringing about a revolution in the cardiac space.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding provided by HAIF Inc.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Not Applicable
Data Availability
Data received from Framingham Heart Study.
